Ireland
--:--IST
Clinical Trials in the EU / 2025-520759-10-00
Authorised, not yet recruiting Phase II

ABCSG 64 / neoGRACE: An open-label, two-arm, randomized phase II study of Sacituzumab Govitecan vs Standard of Care as neoadjuvant therapy for endocrine non-responsive ER+/HER2-negative early breast cancer

2025-520759-10-00 · tracked via the Priya Life Science EU tracker
Sponsor
Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group
Sponsor type
Patient organisation/association
Therapeutic area
Neoplasms
Decision date
09/11/2026
Enrollment target
80
Sites
Austria

Condition studied

endocrine non-responsive ER+/HER2-negative early breast cancer

Investigational medicinal product(s)

PACLITAXELCYCLOPHOSPHAMIDETrodelvy 200 mg powder for concentrate for solution for infusionEPIRUBICIN HYDROCHLORIDEDOCETAXEL

Every trial of Epirubicin, Sacituzumab Govitecan, Docetaxel and Cyclophosphamide across our registers →

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

pCR at time of surgery

Endpoint detail

RCB at time of surgery, Long-term outcome i.e. event free survival (EFS), invasive disease-free survival (IDFS), invasive breast cancer-free survival (IBCFS), distance recurrence-free survival (DRFS) and overall survival (OS)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-520759-10-00 on CTIS ↗ ← All trials in the EU